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Abstract 
 
 There has been little work to date regarding the proper use of covariate 
information in non-inferiority trials. Too often knowledge obtained in the 
superiority setting is applied directly to the non-inferiority setting.  However, due 
to the reversal of the hypotheses and the consequent reversal of the implication of 
error probabilities, this is a dangerous practice. The current work demonstrates 
that in both superiority and non-inferiority, failure to adjust for important 
covariates results in estimates of treatment effect that are biased towards zero with 
standard errors that are deflated. However, as no treatment difference is 
approached under the null hypothesis in superiority and under the alternative in 
non-inferiority, this results in decreased power and nominal or conservative 
(deflated) type I error in the context of superiority, but inflated power and type I 
error under non-inferiority. This occurs regardless of adjustment at 
randomization.  
Generally, it is advised that covariates requiring adjustment be specified 
before the start of the trial.  However, important prognostic factors are not always 
 
vii 
 
known in advance. Thus, a joint statistic for the identification of important 
covariates based on the simultaneous assessment of influence on outcome and 
disparity across treatment groups is developed for the non-inferiority setting. This 
statistic, when calculated for all available covariates in a trial, can be used to rank 
them according to importance. This ranking can be used to identify the subset that 
will optimize the tradeoff between the change in the point estimate of the 
treatment effect and its precision while preserving type I error. This method is 
applied to the Rapid Anticonvulsant Medication Prior to Arrival Trial 
(RAMPART) and its pediatric cohort. 
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Chapter 1 
Introduction 
 
With the increase in the number of efficacious therapies available, the 
non-inferiority trial is growing progressively more popular.  It is often used when 
a current standard of care has already been shown to be effective, but an 
alternative many offer some added benefit such as lower cost, greater ease of 
administration, or greater tolerability.  Thus, a non-inferiority trial seeks to 
address the question of whether a new drug or intervention is “no worse than” a 
current standard of care by some predetermined margin, the non-inferiority 
margin. Under this design, the null hypothesis states that the new drug is worse 
than the standard and the alternative states that it is nearly equal by some pre-
defined amount.
5
 These hypotheses are often formally tested using a confidence 
interval approach in which the null is rejected if the lower bound crosses the pre-
determined non-inferiority margin.
13,21
  Due to this reversal in the hypotheses, the 
implications of type I and type II error are also reversed.
5
  An FDA guidance
41
 
exists for non-inferiority trials, which outlines several key design issues including 
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the proper specification of hypotheses, the choice of active control, the 
determination of the non-inferiority margin, and the appropriate analysis method. 
However, gaps remain in this guidance as well as in the statistical and clinical 
literature, including recommendations for the proper use of covariate information. 
In a PubMed search of phase-III clinical trials published in the last 10 
years containing the word “non-inferiority”, 44.8% of 58 trials utilized complete 
randomization and unadjusted primary analyses. Covariate adjusted 
randomization and appropriate analysis of covariance or stratification was used in 
20.7% of trials.  Covariate adjustment at randomization, but not at analysis was 
done in 25.7%, and adjustment at analysis but not at randomization was done in 
8.6% of the trials.  This review of current practice shows that there is still 
considerable variability in the way that clinical trialists use covariate information, 
a finding that is not surprising considering the lack of attention it has received in 
the non-inferiority literature.  Some feel that primary analyses should always be 
unadjusted as this offers greater interpretability. Others believe that tests of 
baseline imbalance can be used to determine which covariates require adjustment, 
while still others argue that all known prognostic covariates should be included at 
both randomization and analysis.
1,31,32,35,36
 
An issue arises, however, when important prognostic variables are not 
known in advance. In this case, a data-driven method for choosing covariates 
based on both disparity with treatment allocation and influence on outcome is of 
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value. This can be accomplished through a joint statistic that combines these two 
factors to maximize the tradeoff between the change in the point estimate itself 
and its precision.
3,6,7
  While such data-driven techniques could have important 
implications for type I error, the statistic can be designed to reduce this potential 
such that covariates with disparity and influence in the same direction are favored.  
Thus, the treatment estimate is always conservative.  In practice, this statistic can 
be calculated for all available covariates in a trial and ranked according to 
importance of inclusion in analysis to this end.  This work seeks to address (1) the 
impact of failing to adjust for prognostic covariates at either randomization or 
analysis in a non-inferiority trial, (2) the development of the joint statistic for 
disparity and influence, and (3) the practical implications of its use as further 
outlined in the specific aims.   
 
1.1 Motivating Example 
This issue presented itself to the Neurologic Emergencies Treatment Trials 
(NETT) Network during the design of the Rapid Anticonvulsant Medication Prior 
to Arrival Trial (RAMPART).
 
 RAMPART is a non-inferiority trial in the pre-
hospital treatment of status epilepticus, which is a life threatening and debilitating 
disease operationally defined as a seizure lasting for at least five minutes.  The 
current FDA approved treatment for status epilepticus is intravenous (IV) 
lorazepam (4mg-10mg), but as it is difficult to establish an IV in a patient that is 
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actively seizing, there is a need for an equally effective therapy with a simpler 
method of administration.  Intramuscular (IM) administration of a benzodiazepine 
had shown promise as an alternate approach, but was not expected to yield 
superior efficacy.  As such, RAMPART was designed to test the hypothesis that 
IM midazolam (10 mg in adults or 5 mg in children < 13 kg) was non-inferior to 
IV lorazepam (4 mg in adults or 2 mg in children < 13 kg) by a pre-specified 
clinically meaningful amount, the non-inferiority margin. The primary outcome 
was the proportion of subjects with seizure termination prior to emergency 
department (ED) arrival without the use of rescue medication. A total of 893 adult 
and pediatric patients were enrolled.
40
 
The RAMPART trial had many unique aspects including administration of 
treatment in a pre-hospital setting. This required extensive training of the 
Emergency Medical Services (EMS) units across the US and the need to have 
study drug available on each ambulance, making it infeasible to include 
prognostic factors in the randomization algorithm.  Therefore, subjects were 
allocated via complete randomization, without consideration of any potentially 
important prognostic variables, and an unadjusted primary analysis was 
conducted.
40
  
Upon completion of the trial, not only was IM midazolam found to be 
non-inferior to IV lorazepam (Π𝐼𝑉 = 63.6%, Π𝐼𝑀 = 73.4%, 𝑝 < 0.001), but 
results suggested superiority (p<0.001), implying that a change in clinical practice 
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may be warranted.
39
 There were, however, a number of covariates in this trial that 
may have been of prognostic importance, and the exclusion of these covariates 
from the analysis may have had serious implications in the accuracy of the 
estimation of the treatment effect as well as the overall conclusions regarding IM 
midazolam’s non-inferiority to IV lorazepam.  
 
1.2 Specific Aims 
As the impact of covariate adjustment in the non-inferiority setting is less 
understood than in the context of superiority, it is of interest to evaluate the 
impact of failing to include covariates in the analysis of non-inferiority trials and 
to develop a method to aid in the decision to include covariates. Thus, the aims of 
this dissertation are: 
1.) To evaluate differences in the operating characteristics (power, type I 
error, and bias in the treatment estimate as well as its accompanying 
standard error) in the superiority and non-inferiority settings under the 
following four scenarios: 
a. Complete randomization and unadjusted analysis 
b. Complete randomization and adjusted analysis 
c. Covariate adjusted permuted block randomization and unadjusted 
analysis 
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d. Covariate adjusted permuted block randomization and adjusted 
analysis 
 
Hypotheses: 
 For the superiority setting, we hypothesize a reduction in type I 
error probability when covariate adjusted permuted block randomization is 
used with an unadjusted primary analysis (Scenario 1c), and nominal type 
I error for all other scenarios. Furthermore, we expect to see greater 
preservation of power in adjusted analyses as compared to unadjusted 
analyses, with additional preservation occurring in the context of covariate 
adjusted randomization (Scenario 1d). As for bias, we hypothesize 
estimates of treatment effect and standard errors that are biased downward 
toward zero in the context of unadjusted analyses, with greater bias in the 
standard error of the treatment estimate when complete randomization is 
used.  However, we expect minimal bias in the context of adjusted 
analyses. 
   In the non-inferiority setting, we expect a reversal such that type I  
 error is inflated for Scenario 1c (nominal for all other scenarios) and 
 power is inflated for covariate adjusted randomization and analyses.  
 Similarly, we hypothesize that treatment estimates will be biased upward 
 toward zero and the accompanying standard error biased downward in the 
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 context of unadjusted analysis, with greater bias in the standard error of  
 the treatment estimate in the context of complete randomization. In 
 addition, we expect minimal bias in the context of adjusted  analyses. 
 
2.) To develop a joint statistic to quantify the impact of adjustment for a given 
binary covariate based on its association with outcome (influence) and its 
imbalance across treatment groups (disparity) 
 
 Hypotheses: 
  We believe that the work of Canner
6,7 
and Beach and Meier
3
 can 
 be extended for use in the non-inferiority framework with a binary 
 outcome through the introduction of the non-inferiority margin.  We 
 expect that this statistic will fully quantify the impact of adjustment for a 
 given covariate and can be used to rank available covariates in terms of 
 relative importance.  Finally, by choosing an appropriate subset of 
 covariates to include in analysis based on this ranking, we believe that 
 we can optimize reduction in type I error.  
 
 
8 
 
3.) To apply this statistic to rank the available covariates in a real trial 
application and evaluate the impact of adjustment on the estimate of 
treatment effect 
  
 Hypotheses: 
  We believe that, when applied to the RAMPART study as a whole 
 and also to the pediatric subset, the joint statistics developed in Aim 2 will 
 be able to identify the most appropriate subset of covariates to include in 
 the analysis.  We also believe that inclusion of these covariates will result 
 in an estimate of treatment effect that is more precise and more 
 conservative in terms of type I error.  
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Chapter 2 
Review of Literature 
 
2.1 Non-Inferiority Trials 
Non-inferiority trials are typically used in situations in which a standard of 
care has already been established to be superior to placebo.  However, a new 
treatment may provide potential advantages, such as a reduction in costs, greater 
ease of administration, or fewer side effects.  In such a situation, this new 
candidate therapy may not be expected to be superior to standard of care, but if it 
alleviates some of the limitations and is “no worse” by some pre-specified 
amount, then it may be adopted by the clinical community.  Thus, a non-
inferiority trial seeks to provide a statistical answer to this question of “no worse 
than” by showing that the experimental treatment is non-inferior to the standard of 
care by some pre-specified amount, referred to as the non-inferiority margin (𝑑). 
There are many challenges that arise in the design and analysis of such a trial 
including the proper specification of hypotheses, the determination of the 
probability of success in the standard of care group and the non-inferiority 
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margin, the appropriate analysis method to employ, and the impact of covariate 
adjustment. 
A fundamental difference between a superiority trial and a non-inferiority 
trial is the way in which hypotheses are stated.
5
  The typical null hypothesis for a 
one-sided superiority trial is that the difference is less than or equal to zero, 
whereas the alternative hypothesis is that the difference is greater than zero 
(experimental treatment is superior to placebo): 
𝐻0 ∶  𝜋𝑇 − 𝜋𝑃  ≤ 0  𝑜𝑟 𝜋𝑇  ≤  𝜋𝑃 
               𝐻1 ∶  𝜋𝑇 − 𝜋𝑃  > 0  𝑜𝑟 𝜋𝑇  >  𝜋𝑃 
where 𝜋𝑇 is the probability of success in the treatment group and 𝜋𝑃 is the 
probability of success in the placebo group. In the framework of a non-inferiority 
trial, the null hypothesis is that the difference between the efficacy of the new 
treatment (𝜋𝑇) and standard of care (𝜋𝑆) is less than or equal to the non-
inferiority margin (δ) versus the alternative hypothesis which states that this 
difference is greater than δ: 
𝐻0 ∶  𝜋𝑇 − 𝜋𝑆  ≤ −𝑑  𝑜𝑟 𝜋𝑇  ≤  𝜋𝑆 −  𝑑 
𝐻1 ∶  𝜋𝑇 − 𝜋𝑆  > −𝑑  𝑜𝑟 𝜋𝑇  >  𝜋𝑆 −  𝑑 
When the hypotheses are stated in terms of probabilities of success as above, the 
non-inferiority margin is often negative because we expect the new treatment to 
be less efficacious than the standard of care under the null.
5
 However, if the 
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hypotheses are stated in terms of the proportion of failures in each treatment 
group, then we would expect a positive non-inferiority margin. 
 Regardless, we are not comparing the candidate treatment to a placebo as 
this would be unethical in the presence of a viable treatment.  Instead, we are 
using the standard of care for our comparison.
5
 This forces us to make an 
assumption about the probability of success in the standard of care group, which 
we can only do in light of previous studies in the same patient population.  This is 
often referred to as the constancy assumption because we must assume that this 
treatment effect is constant across studies.
13,41
 In addition, the lack of a placebo 
group forces us to make the assumption of assay sensitivity, which assumes that, 
had a placebo group been included, the standard of care would have shown this 
same treatment effect in comparison.  If non-inferiority is demonstrated, this 
assumption can be evaluated, but never formally proven, through the comparison 
of confidence intervals for standard of care in the current study and in the 
historical study used to establish superiority over placebo.
13,41 
 Another design challenge in a non-inferiority study is that of choosing the 
proper non-inferiority margin (𝛿). In 2006, the Committee for Proprietary 
Medicinal Products for Human Use (CHMP) guidelines
10
 suggested that using an 
absolute difference in proportions of 10% is appropriate, whereas the FDA
41
, 
borrowing from vaccine trials, proposed a stepwise function based on the 
probability of success for the standard of care (𝜋𝑆) as follows: 
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𝜋𝑆  < 0.8 →  𝛿 = 0.20 
0.8 ≤  𝜋𝑆  < 0.9 →  𝛿 = 0.15 
𝜋𝑆  ≥ 0.9 →  𝛿 = 0.10 
Romel
34
 suggested a function that was similarly dependent on the reference 
treatment effect, but that was continuous: 
−0.223√{𝜋𝑆 (1 − 𝜋𝑆 )}
3
 
The current practice in the determination of the non-inferiority margin requires 
the investigator to place the experimental treatment on a continuum with the 
effect of placebo at one end and the effect of standard of care at the other.  Then, 
the full distance from placebo to standard of care can be derived using the 
constancy assumption, and the distance from experimental treatment to standard 
of care, which is the non-inferiority margin, can be based on clinical relevance.  
Finally, the distance between placebo and experimental therapy can be calculated 
as
11
: 
(1 − 𝛿) ∗ (𝜋𝑆 − 𝜋𝑃) 
All of the methods discussed previously deal with a non-inferiority margin based 
on an absolute difference in proportions, a technique which Garrett
18
 condemns 
for being dependent on the probability of success for standard of care, and offered 
the use of the odds ratio as a viable alternative that is not subject to this constraint.  
In this case, the margin corresponds to smaller absolute differences in proportions 
when the reference probability of success approaches either 0 or 1, which is 
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consistent with the goals of the regulatory documents, and it is easily incorporated 
into generalized linear models.
 
There has also been much debate in the statistical and clinical literature 
about the best approach to analyze data from a non-inferiority trial.  In 1977, 
Dunnett and Gent
12
 proposed the following test statistic based on the 
incorporation of the non-inferiority margin into the test for a difference in 
proportions in the context of a superiority hypothesis: 
𝑧 =
𝑝1 − 𝑝2 −  𝛿
√𝑣𝑎𝑟(𝑝1 − 𝑝2)
 
where 𝑣𝑎𝑟(𝑝1 − 𝑝2) =
𝑝1(1−𝑝1)
𝑛1
 + 
𝑝2(1−𝑝2)
𝑛2
, 𝑝𝑖 is the probability of success in 
treatment i, 𝑛𝑖  is the number of patients in treatment 𝑖, and 𝑖 = 1,2.  Another 
hypothesis testing approach which has been proposed by Hung et al.
21
 and 
endorsed by the FDA guidance
41
 combines information from the trial(s) of the 
historical control versus placebo with information from the current non-inferiority 
trial as follows: 
𝑍 =
𝑙𝑜𝑔(?̂?) − 𝑙𝑜𝑔(?̂?) − (1 − 𝜆)(𝑙𝑜𝑔(𝐶?̂?) − 𝑙𝑜𝑔(𝑃0̂))
√𝜎𝑇𝐶
2 + (1 − 𝜆)2𝜎𝑃𝐶𝑂
2
 
where 𝑙𝑜𝑔(?̂?) − 𝑙𝑜𝑔(?̂?) is the log relative risk from the non-inferiority trial of 
treatment versus standard of care with variance equal to 𝜎𝑇𝐶
2 , 𝑙𝑜𝑔(?̂?𝑂) −
𝑙𝑜𝑔(𝑃0̂) is the log relative risk from the trial(s) of standard of care versus placebo 
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with variance equal to 𝜎𝑃𝐶𝑂
2 , and 𝜆 is the percent of standard of care effect which 
must be preserved. 
 Several confidence interval approaches have also been proposed in which 
the lower bound of the two-sided 95% confidence interval for the effect of 
treatment versus standard of care is compared to either (1) the point estimate of 
the effect of standard of care versus placebo found in previous trials, (2) the upper 
bound of the two-sided 95% confidence interval of the effect of standard of care 
versus placebo, or (3) a pre-specified fixed margin of clinical significance. Either 
of the latter two methods results in conservative or nominal type I error, whereas 
the first can result in increased type I error due to the fact that the variance of the 
effect of standard of care versus placebo is not considered, and thus appropriate 
weight is not given to trials of different sizes.
21,41 
In light of these findings, the 
current confidence interval approach is accomplished by calculating a two-sided 
95% confidence interval of the risk difference, relative risk, or odds ratio of the 
treatment effect, and comparing its lower bound to a non-inferiority margin.
18
 
This technique is considered by many to be better than the typical hypothesis 
testing approach because it offers additional information such as the estimates of 
the minimum and maximum treatment effect. 
 The subject of covariate adjustment in non-inferiority trials remains 
lacking in the literature.  Since the statement of null and alternative hypotheses 
yields a different implication for type I and type II errors when compared to the 
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framework of superiority, it is suspected that the impact of failure to adjust for 
important covariates may also differ in this setting.  In non-inferiority trials, type I 
error (or α) is defined as claiming non-inferiority when the new treatment is 
actually worse than the active control, and type II error (or β) is defined as 
claiming lack of non-inferiority when the experimental treatment is non-inferior 
to the active control.
5
 Because of this important difference, our understanding of 
covariate adjustment cannot easily be extended from the superiority to the non-
inferiority setting.  Thus, there is a great need to further evaluate the impact of 
covariate adjustment on operating characteristics in the context of non-inferiority 
trials. 
 
2.2 Randomization 
In clinical trials, the variability present in the outcome of interest is large 
in comparison to the expected magnitude of the treatment effect.  The act of 
randomization seeks to control this variability through the elimination of selection 
bias as well as accidental bias in treatment allocation.  Selection bias can be 
controlled by the introduction of randomness, which forms the basis for 
probabilistic approaches to hypothesis testing.  However, randomization also 
seeks to control accidental bias by ensuring that there are no systematic 
differences between treatment groups.
14,19,30,44
  The type of randomization that is 
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used affects the amount of resulting randomness and balance, which can impact 
the estimation of treatment effect if not considered at the analysis phase.
25,44 
In complete (or simple) randomization, patients are assigned to treatment 
groups with equal probability.  This results in perfect randomness but can often 
lead to groups of unequal size, especially given small sample sizes. In fact, when 
we randomize N patients with probability p=0.5 to two treatment groups, the 
probability that each group contains an equal number of patients is: 
𝑃[𝑋 = 𝑥] = (
𝑁
𝑁
2⁄
)
1
2𝑁
 
Thus, if N equals 100, the probability that randomization will yield exactly 50 
patients per group is approximately 8%.  Furthermore, given calculation of mean 
and variance from the binomial distribution, the same scenario yields a 95% 
confidence interval of the number of patients assigned to either Treatment A or 
Treatment B as roughly equal to: 
𝑁𝐴 𝑜𝑟 𝐵  ± 10 
As such, we can expect more than a 60/40 imbalance in favor of one treatment 
over the other 5% of the time.
30 
 Permuted block randomization, as introduced by Hill
19
, is achieved by first 
choosing a block size, which can be any multiple of the number of treatments to 
be evaluated. Then, the order of treatment assignments within each block is 
randomly permuted, such that perfect balance is achieved after the completion of 
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each block. Thus, if a trial consisted of two treatments (A and B) as discussed 
previously, and a block size of two was chosen, treatment assignments within 
each block could take the form of either AB or BA.  In this manner, the maximum 
imbalance that could result would be one, yet the proportion of deterministic 
assignments would be 50%.
30
  Thus, permuted block randomization results in a 
much tighter treatment balance than complete randomization, but with much less 
randomness.
44
 When the block size is equal to the sample size, permuted block 
randomization becomes a random allocation design.  This results in near perfect 
randomness (some deterministic assignments may occur for the last subject(s) 
enrolled) as well as perfect balance at the conclusion of the trial.
44
    
 Any of the randomization strategies above can also be used in the presence 
of important covariates. A prognostic covariate is any variable that is significantly 
associated with outcome, and the exclusion of such factors from the 
randomization scheme or analysis may have important implications for a test of 
treatment effect.  Thus, when there is a known prognostic covariate, adjustment is 
recommended.
1,22,29,31,36
 This is often accomplished by first categorizing 
covariates, and then performing a given randomization scheme (e.g., complete 
randomization, random allocation, permuted block) within each stratum.  In so 
doing, balance is achieved not only with respect to the number of patients within 
each treatment group, but also with respect to the distribution of covariates within 
these groups.  This covariate adjusted randomization imposes additional balance, 
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which yields greater power in detecting treatment effects, serves to protect against 
model misspecification, and ensures greater power for subgroup and interim 
analyses.
22,25,35,38
  
 
2.3 The Impact of Failing to Adjust for Covariates in Analysis 
 It has been shown in a superiority setting that failure to adjust for 
important prognostic covariates at analysis leads to biased estimates of the 
treatment effect, the direction and magnitude of which is dependent on the 
strength of association between the covariate and outcome, as well as the level of 
covariate imbalance across treatment arms.
9,16,17,23,26,29,33,35,38
 
 Robinson and Jewell
33
 show that in a linear setting, a strong association 
between covariate and outcome decreases the variance of the treatment effect in 
the context of adjustment through the reduction of residual variance, whereas a 
strong association between covariate and treatment increases the variance of the 
treatment effect.  Thus, precision is based on these competing effects.  As for 
logistic regression, both a strong association between covariate and outcome and a 
strong association between covariate and treatment result in increased variance 
given adjustment.
33
  Therefore, in logistic regression, there is always an automatic 
loss in precision when we adjust for covariates, regardless of whether or not they 
are predictive of outcome.
26
 Thus, the standard error of the treatment effect in an 
unadjusted analysis will be deflated as compared to the standard error in the 
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adjusted analysis. However, it is important to note that this bias in the standard 
error of the estimate of the treatment effect is coupled with a bias in the treatment 
estimate itself.
33
 
 Gail et al.
17
 illustrate the nature of this bias in the treatment estimate via 
Taylor series approximation in a nonlinear setting. In a linear setting, the 
treatment effects in an adjusted versus an unadjusted model are equivalent.  In the 
nonlinear setting (i.e., in the context of logistic regression), they quantify the 
discrepancy between the unadjusted treatment effect estimate and the adjusted 
treatment effect estimate as:  
𝛽𝑡𝑟𝑡
∗ − 𝛽𝑡𝑟𝑡 = 
1
2
𝛽𝑐𝑜𝑣
2 𝜎𝑐𝑜𝑣
2 [
ℎ′′(𝛽𝑡𝑟𝑡,)
ℎ′(𝛽𝑡𝑟𝑡)
−
ℎ′′(𝛽0)
ℎ′(𝛽0)
] 
where 𝛽𝑡𝑟𝑡
∗ is the treatment effect when the covariate is not included, 𝛽𝑡𝑟𝑡 is the 
treatment effect when the covariate is included, 𝛽𝑐𝑜𝑣 is the covariate effect, 𝜎𝑐𝑜𝑣
2  is 
the variance of the covariate, ℎ(𝜂) =
exp (𝜂)
1+exp (𝜂)
, 𝜂 = 𝛽0 + 𝛽𝑡𝑟𝑡(𝑇𝑟𝑡) + 𝛽𝑐𝑜𝑣(𝐶𝑜𝑣), 
and 𝛽0 is the intercept. They demonstrate that this discrepancy is nonzero (i.e., the 
unadjusted effect will always be biased) except when there is no treatment effect, 
when there is no association between covariate and outcome, or when the 
variance of the covariate is zero. Furthermore, Gail et al.
17
 show that the bias 
tends to be such that the unadjusted effect will underestimate the adjusted effect if 
the treatment effect is positive, and this outweighs any benefit in standard error.  
Thus, the overall result is a decrease in power when failing to adjust, and this 
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effect holds even when important prognostic covariates are perfectly balanced.
3,15-
17,26,33
 
 In addition to the strength of association between covariate and outcome 
and covariate and treatment, the marginal distribution of the treatment itself also 
plays a role in the variance of the treatment estimate in logistic regression such 
that the highest variance is achieved when the probability of success is 0.5. For 
this reason, the operating characteristics derived from analyses of a clinical trial 
may be sensitive to assumptions regarding the probability of success in the control 
arm and the minimum clinical difference. 
 The use of covariate adjusted randomization in the design of a clinical trial 
introduces correlation between treatment and covariate.  As presented by Kahan 
and Morris
23
, in the context of superiority, the variance of the treatment difference 
within a stratum, given a continuous outcome, can be found from the following 
expression: 
𝑣𝑎𝑟(𝑌1̅ − 𝑌2̅) =  𝑣𝑎𝑟(𝑌1̅) +  𝑣𝑎𝑟( 𝑌2̅) −  2𝑐𝑜𝑣(𝑌1̅, 𝑌2̅) 
In randomization schemes that do not use covariate information, the mean 
outcomes for treatment one (𝑌1̅) and treatment two (𝑌2̅) can be assumed to be 
independent.  Therefore, the last term would be equal to zero, and the previous 
equation, given equal variance of the treatment groups, would simplify to: 
𝑣𝑎𝑟(𝑌1̅ − 𝑌2̅) =
2𝜎2
𝑛
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However, in the absence of this assumption of independence, the correlation 
between 𝑌1̅and 𝑌2̅ is 𝜌, and the following is applicable: 
𝑣𝑎𝑟(𝑌1̅ − 𝑌2̅) =
2𝜎2
𝑛
− 
2𝜌𝜎2
𝑛
=  
2𝜎2
𝑛
(1 − 𝜌) 
Thus, if we were to conduct an unadjusted analysis in the context of covariate 
adjusted randomization, the estimated variance of the treatment effect would be 
biased upwards, leading to decreased power and type I error when the outcome is 
continuous.
23,29,38
  The magnitude of this bias is directly associated with not only 
the strength of association between covariate and outcome, but also with the 
strength of association between covariate and treatment (i.e., the level of 
confounding). 
1,31,35
  
 In light of all of the statistical evidence in favor of adjusted analyses, it is 
currently recommended that important prognostic covariates that are included in 
the randomization scheme should also be included in the final analysis in the form 
of a properly specified analysis of covariance.
1,22,29,31,36
  Whereas failure to adjust 
for covariates in the superiority setting decreases type I error and power as 
described previously, failure to adjust in non-inferiority may actually increase 
type I error and power, but there has only been one paper to date on this subject.
18
 
Thus, the impact of covariate adjustment in the context of non-inferiority is an 
important issue worthy of further investigation. 
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2.4 The Impact of Tests of Baseline Imbalance 
 Given that the impact of failing to adjust for important prognostic 
covariates is dependent on both the strength of association with outcome as well 
as the level of imbalance, it has become common practice among some clinical 
trialists to perform statistical tests of baseline covariates, and then to adjust for 
those covariates which are significantly imbalanced. Although this practice has 
been condemned in the statistical literature
1,31,32,35,36
, it remains prevalent, the 
rationale being that treatment groups should be as similar as possible for an 
unbiased assessment of the treatment effect.   According to Altman and Dore
2
, 46 
of the 80 trials published in four leading medical journals in 1987 conducted tests 
of baseline imbalance resulting in roughly 600 tests, of which only 24 (4%) were 
significant at the 5% level  Pocock et al.
31
 find similar trends in 2002.  Twenty-
four (24) out of the 50 trials that they investigated (48%) employed such tests, of 
which 18 out of 299 total tests (6%) were significant. Thus, as Altman
1
 eloquently 
states, “performing significance tests to assess baseline variables is to assess the 
probably of something having occurred by chance when we know that it did occur 
by chance.” As a result, this practice serves as merely a test of the process of 
randomization itself.  Balance is, in fact, not necessary for valid inference, but 
rather concerns the precision of the treatment effect.  Furthermore, the exclusion 
of a highly influential covariate even if it has only a very small (statistically 
insignificant) imbalance across treatment arms will influence the final analysis, 
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whereas the exclusion of a highly imbalanced covariate with no association with 
outcome will have no effect.
1,31,36
 
 The practice of testing for baseline imbalance also has important 
implications for the type I error and power of the final analysis.  Following 
notation given in an explanation by Senn
35
 using a continuous outcome and a 
single continuous covariate, an unadjusted test of treatment effect under the null 
hypothesis in superiority is as follows: 
𝑑𝑦
√𝜎𝑦
2 (
1
𝑛𝑡𝑟𝑡
+
1
𝑛𝑐𝑜𝑛𝑡
)
≥ 𝑍𝛼 
where 𝑑𝑦 is the treatment effect, 𝜎𝑦
2 is the variance of the treatment effect, 𝑛𝑡𝑟𝑡 
and 𝑛𝑐𝑜𝑛𝑡 are the sample sizes of the treatment and control groups respectively, 
and 𝑍𝛼 is the (1-𝛼)x100% standard normal quantile.  Senn derives the following 
expression for the size of a test of treatment effect conditional on a covariate X: 
𝛼(𝑑𝑥) = 𝑝
[
 
 
 
𝑍 ≥
𝑍𝛼
√1 − 𝜌2
−
𝜌𝑑𝑥
√(1 − 𝜌2𝜎𝑥2 (
1
𝑛𝑡𝑟𝑡
+
1
𝑛𝑐𝑜𝑛𝑡
)
]
 
 
 
 
where 𝛼(𝑑𝑥) is the conditional size of the test, 𝑑𝑥 is the effect of the covariate, 𝜎𝑥
2 
is the variance of the covariate effect, and 𝜌 is the strength of the association 
between covariate and outcome.  Finally, if we let 𝑑𝑥
∗  represent Senn’s 
“standardized prognostic imbalance” between treatment groups (i.e., the two 
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sample Z statistic comparing mean covariate values across treatment groups), this 
reduces to: 
𝛼(𝑑𝑥) = 𝑝 [𝑍 ≥
𝑍𝛼
√1 − 𝜌2
−
𝜌𝑑𝑥
∗
√(1 − 𝜌2)
] 
From this, we can see that for a given strength of the covariate (𝜌), as the level of 
imbalance increases the size of the test also increases in a non-linear fashion in 
the superiority setting.  Furthermore, when the covariate is negatively associated 
with outcome, increasing levels of imbalance result in increasingly conservative 
unadjusted tests.  Similarly, when both the covariate and the treatment are 
positively associated with outcome, an imbalance favoring the treatment group 
will increase power, the magnitude of which will increase as the strength of the 
covariate increases.
35
 On the other hand, when a covariate is negatively associated 
with outcome and the treatment effect is positive, an imbalance favoring the 
treatment group will result in decreased power.
8
 Finally, it is important to note 
that such effects on type I error and power occur prior to the cutoff for 
significance (5%) of a baseline test of imbalance.  Thus, not only does this 
practice impact the error probabilities of the final analysis, but is also offers no 
guarantee that the covariate imbalance will not influence overall 
conclusions.
1,3,8,29,35,36
 However, this practice of testing for baseline imbalance, 
much like covariate adjustment in general, has received little attention in the non-
inferiority setting, and thus it is a topic worthy of further investigation. 
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2.5 Quantifying the Impact of Adjustment for a Given Covariate Based on 
Influence and Disparity 
 
 Much of the regulatory and statistical literature agrees that covariate 
adjustment should be specified a priori and that those covariates included in 
randomization should also be included in the final analysis.
22,36
 However, 
methods for identifying important covariates that are not known in advance are 
lacking. While significance testing continues to be a prominent practice, an 
alternative has been proposed that may not have the same impact on type I error.  
 As previously stated, the impact of including a given covariate in analysis 
can be quantified in terms of its association with treatment and its association 
with outcome. In practice, these correlations are often evaluated in isolation 
despite the fact that they represent competing goals.  However, the simultaneous 
evaluation of these factors can reveal the optimal estimate of the treatment effect 
in terms of both the point estimate itself and its precision.  
  At the Society for Clinical Trials Annual Scientific Sessions in 1981, 
Canner
6
 presented such a method for the inclusion of a binary covariate given a 
binary outcome and zero treatment effect, which was later included in a paper by 
Beach and Meier
3
.  They present the following condensed 2x2x2 table in which 
the number in each cell can be obtained by multiplying the proportions of failure 
(top expression) by the total number of subjects (bottom expression).  
 
 
26 
 
Table 2.5.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate  
  Cov=0 Cov=1   
Control 𝑝(1 − 𝑟2) 
𝑁(1 +  𝑟1)/2 
𝑝(1 + 𝑟2) 
𝑁(1 −  𝑟1)/2 
𝑝(1 − 𝑟1𝑟2) 
𝑁 
Trt 𝑝(1 − 𝑟2) 
𝑁(1 −  𝑟1)/2 
𝑝(1 + 𝑟2) 
𝑁(1 +  𝑟1)/2 
𝑝(1 + 𝑟1𝑟2) 
𝑁 
  𝑝(1 − 𝑟2) 
𝑁 
𝑝(1 + 𝑟2) 
𝑁 
𝑝 
2𝑁 
 
where 𝑁 is the number per group, 𝑝 is the proportion of failures, 𝑟1is the 
correlation between treatment and covariate,and 𝑟2 can be derived as follows: 
𝑟2 =
𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√𝑝(1 − 𝑝)
𝑝
. 
From this, a statistic for the association between covariate and outcome (ZI), 
which Canner calls “influence”, was developed in which the numerator represents 
the marginal difference between the overall proportion of failures among those 
with the covariate verses those without and the denominator represents its 
accompanying variance. 
𝑍𝐼 =
𝑝(1 + 𝑟2) − 𝑝(1 − 𝑟2)
√2𝑝𝑞/𝑁
=
√2𝑁𝑝𝑟2
√𝑝𝑞
 
where 𝑞 = 1 − 𝑝.  He similarly derives a statistic for the association between 
covariate and treatment (ZD), which he refers to as “disparity”, based on the 
number in the treatment group with the covariate minus the number in the 
treatment group without the covariate.       
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𝑍𝐷 =
[(
𝑁
2
) (1 + 𝑟1) − (
𝑁
2
)(1 − 𝑟1)]√2𝑁
√𝑁2
 
Finally, he combines these to produce a joint statistic (ZU) which gives equal 
weight to disparity and influence.
3,6
 
𝑍𝑈 =
𝑍𝐼 𝑍𝐷
√2𝑁
=
𝑝(1 + 𝑟1𝑟2) − 𝑝(1 − 𝑟1𝑟2)
√2𝑝𝑞/𝑁
=  
√2𝑁𝑝𝑟1𝑟2
√𝑝𝑞
  
This ZU represents the importance of adjustment for a given covariate, and when 
calculated for all candidate covariates in a dataset and ranked, it can be used to 
evaluate their relative importance. While this joint statistic is of great theoretical 
importance, it suffers from the impractical assumption that there is no association 
between treatment and outcome (i.e., the adjusted statistic, ZA, is equal to zero). In 
order to accommodate non-zero treatment effect, a third layer of correlation must 
be added.  Beach and Meier
3
 provide this extension in the context of continuous 
outcome in terms of regression parameters, which Canner
7
 later presents via 
correlation.   
𝑍𝐴 =
𝑏𝑦1.2
√𝑣𝑎𝑟𝑏𝑦1.2̂
=
𝑟𝑦1.2√𝑁 − 3
√1 − 𝑟𝑦1.2
2
 
where 𝑏𝑦1.2 is the partial regression coefficient for outcome (𝑌) and treatment 
(𝑋1) given covariate (𝑋2) and 𝑟𝑦1.2 is the partial correlation coefficient for 
outcome and treatment given covariate. This can be expanded as follows: 
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𝑍𝐴 =
(𝑟𝑦1 − 𝑟𝑦2𝑟12√𝑁 − 3)
√1 − 𝑟𝑦1
2 − 𝑟𝑦2
2 − 𝑟12
2 + 2𝑟𝑦1𝑟𝑦2𝑟12
 
given the well- known relationship 
𝑟𝑦1.2 =
𝑟𝑦1 − 𝑟𝑦2𝑟12
√(1 − 𝑟𝑦2
2 )(1 − 𝑟12
2 )
 
where 𝑟𝑦1is the correlation between outcome and treatment, 𝑟𝑦2 is the correlation 
between outcome and covariate, and 𝑟12 is the correlation between treatment and 
outcome. If we subtract 𝑍𝐴 from 𝑍𝑈, we can obtain a value for the importance of 
adjustment controlling for the treatment effect.
7 
  
 These methods are sufficient to fully quantify the impact of adjustment for 
a single covariate or multiple covariates given that they are independent of each 
other.  However, in a real trial setting, a strictly additive model is rarely sufficient. 
Although theoretical evaluations of this scenario become increasingly impractical 
as the number of important covariates increases, Berger
4
 proposes an alternate 
method for the evaluation of disparity in which the first covariate is selected in the 
usual way, but subsequent covariates are conditioned such that the adjusted 
discrepancy is the weighted average of the disparity in each of the strata formed 
by the existing covariates.  
 The impact on type I error of these data driven methods for covariate 
selection is not well understood even in the context of superiority as they have not 
been well adopted by the clinical trials community.  In non-inferiority, it has been 
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shown that failure to include important covariates increases type I error.
18,27
 Thus, 
these methods are worth further evaluation.  The following three chapters consist 
of three original papers designed to build upon previous research in the areas of 
covariate adjustment at randomization and analysis, methods for covariate 
selection when prognostic factors are not known a priori, and practical 
application in accordance with the three aims as previously stated.  
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Chapter 3 
Aim 1:  
The Impact of Covariate Adjustment at Randomization and 
Analysis for Binary Outcomes: Understanding Differences 
Between Superiority and Non-Inferiority Trials 
 
The question of when to adjust for important prognostic covariates often 
arises in the design of clinical trials, and there remain various opinions on whether 
to adjust during both randomization and analysis, at randomization alone, or at 
analysis alone.  Furthermore, little is known about the impact of covariate 
adjustment in the context of non-inferiority designs.  The current simulation-
based research explores this issue in the non-inferiority setting, as compared to 
the typical superiority setting, by assessing the differential impact on power, type 
I error, and bias in the treatment estimate as well as its standard error, in the 
context of logistic regression under both complete and covariate adjusted 
permuted block randomization algorithms.  
In both the superiority and non-inferiority settings, failure to adjust for 
covariates that influence outcome in the analysis phase, regardless of prior 
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adjustment at randomization, results in treatment estimates that are biased toward 
zero, with standard errors that are deflated.  However, as no treatment difference 
is approached under the null hypothesis in superiority and under the alternative in 
non-inferiority, this results in decreased power and nominal or conservative 
(deflated) type I error in the context of superiority, but inflated power and type I 
error under non-inferiority.  Results from the simulation study suggest that, 
regardless of the use of the covariate in randomization, it is appropriate to adjust 
for important prognostic covariates in analysis, as this yields nearly unbiased 
estimates of treatment as well as nominal type I error. 
 
3.1 Introduction 
The non-inferiority trial design is growing progressively more popular as 
the need for comparable therapies with secondary advantages increases. The 
challenges that arise in the design and analysis of such a trial have been discussed 
in the FDA Guidance on non-inferiority trials
41
 as well as methodological 
research on proper specification of hypotheses, the choice of active control, 
determination of the non-inferiority margin, and the appropriate analysis 
method.
5,11-13,18,22 
However, critical gaps in the literature remain regarding key 
design issues, specifically the impact of covariate adjustment at both 
randomization and at the analysis phase.  
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In a PubMed search of phase-III clinical trials published in the last ten 
years containing the word “non-inferiority”, 44.8% of 58 trials utilized complete 
randomization and unadjusted primary analyses. Covariate adjusted 
randomization and appropriate analysis of covariance or stratification was used in 
20.7% of trials.  Covariate adjustment at randomization, but not at analysis was 
done in 25.7%, and adjustment at analysis but not at randomization was done in 
8.6% of the trials.  This review of current practice shows that there is still 
considerable variability in the way that clinical trialists use covariate information, 
a finding that is not surprising considering the lack of attention it has received in 
the non-inferiority literature.   
This chapter expands the research on covariate adjustment in the non-
inferiority setting by examining the impact of adjustment at randomization as well 
as at analysis using logistic regression models. A simulation study is conducted to 
examine the operating characteristics in both superiority and non-inferiority 
settings.  Section 1.2 reviews the existing statistical literature on covariate 
adjustment. Sections 1.3 and 1.4 present the simulation methods and results, and 
Section 1.5 discusses the differential impact of covariate adjustment in these two 
settings. 
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3.2 Existing Literature 
 Little work has been published to date to examine the impact of covariate 
adjustment at both randomization and analysis in the context of non-inferiority 
trials. Garrett
18
 explains that, due to the reversal of hypotheses from the 
superiority setting, there is also a reversal of the impact of errors.  Thus, he 
cautions readers that the power and type I error is inflated when important 
prognostic factors are ignored in the non-inferiority setting.  However, this work 
does not take into account the potential impact of the randomization scheme.   
It has been shown in a superiority setting that failure to adjust for 
important prognostic covariates at either randomization or analysis leads to biased 
estimates of the treatment effect, the direction and magnitude of which is 
dependent on the strength of association between the covariate and outcome, as 
well as the level of covariate imbalance across treatment arms.
9,16,17,23,26,29,33,35,38 
Gail et al.
17
 illustrate the nature of this bias via Taylor series approximation in a 
nonlinear setting.  They show that in a linear setting, the estimated treatment 
effect in an adjusted versus in an unadjusted model are equivalent.  In the 
nonlinear (i.e., the logistic) setting, they quantify the discrepancy between the 
adjusted treatment effect estimate and the unadjusted treatment effect estimate 
and demonstrate that this discrepancy is nonzero (i.e., the unadjusted effect will 
always be biased) except when there is no treatment effect, when there is no 
association between covariate and outcome, or when the variance of the covariate 
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is zero. Furthermore, Gail et al. show that the bias tends to be such that the 
unadjusted effect will underestimate the adjusted effect if the treatment effect is 
positive, resulting in a decrease in power, and that this effect holds even when 
covariates are perfectly balanced.  As Robinson and Jewell
33
 point out, this 
underestimation of the treatment effect when failing to adjust for covariates 
outweighs any benefit in standard error.
3,15,16,17,26,33
  
The impact of covariate adjustment at randomization has been evaluated in 
the context of superiority.  Kahan and Morris
23
 illustrate that, for continuous, 
binary, and time-to-event outcomes, stratified randomization creates correlation 
between treatment arms.  Thus, unadjusted analyses in this context result in 
decreased power and type I error, as well as inflated standard errors of the 
treatment effect. 
In light of the statistical evidence in favor of adjusted analyses, it is clear 
that important prognostic covariates that are included in the randomization 
scheme should also be included in the final analysis in the form of a properly 
specified analysis of covariance,
22,29,36 
and, in fact, this results in unbiased 
estimates of treatment effect, as well as nominal power and type I error.  
However, the full impact of covariate adjustment in the non-inferiority setting 
remains to be demonstrated and is a topic worthy of further investigation. 
 
 
 
35 
 
3.3 Simulation Studies 
Parameters are specified according to both the hypothesis of interest (null 
or alternative) and the scenario of interest (superiority or non-inferiority).  Four 
simulation studies were designed to perform complete randomization and 
covariate adjusted permuted block randomization in the context of superiority and 
non-inferiority designs.  All simulations conducted both unadjusted and adjusted 
analyses based on the following models: 
𝑈𝑛𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑: ln (
𝜋
1 − 𝜋
) =  𝛽0 + 𝛽1𝑇𝑟𝑡 
                           𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑: ln (
𝜋
1−𝜋
) =  𝛽0 + 𝛽1𝑇𝑟𝑡 + 𝛽2𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒                     
The probability of success in the control group (𝜋𝐶) was set at 80%.  This value 
was chosen based on a non-inferiority setting where the active control may have a 
high probability of success however the experimental treatment offers other 
advantages such as fewer side effects.   
 
3.3a Simulation Parameters 
The probability of success in the treatment group (𝜋𝑇), the sample size, 
and the pre-determined margin were differentially specified depending on the 
statistical hypothesis to be tested (superiority or non-inferiority), but the 
simulation strategy remained the same.  For the superiority setting, the probability 
of success in the treatment group was set at 90% in order to mimic a trial with an 
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expected absolute difference in treatment of 10%.  The null hypothesis is 
𝐻0: 𝜋𝐶 = 𝜋𝑇 = 0.80, and the alternative is 𝜋𝐶 = 0.80 and 𝜋𝑇 = 0.90.  Thus, 𝛽1 
is estimated to be ln(1) = 0 under the null hypothesis and ln(2.25) =  0.811  
under the alternative.  This information was then used to calculate the total sample 
size of 𝑁 = 392 subjects in order to ensure power of 80% when there was no 
effect of the covariate (𝛽2 = 0).   
The value of 𝛽2was allowed to vary from -3.0 to 3.0 in increments of 0.5 
in order to evaluate the effect of strength of covariate on operating characteristics, 
and equations (1) and (2) above were used to derive the intercept, 𝛽0, for each 
scenario.  Although it is not expected that any covariate would have a coefficient 
as high as 3.0, this range was included in the simulation to examine the theoretical 
setting.  
 For the case of non-inferiority, we set the non-inferiority margin at 0.10, 
resulting in the following hypotheses:   
𝐻0:  𝜋𝐶 − 𝜋𝑇 ≥ 0.10 
𝐻1:  𝜋𝐶 − 𝜋𝑇  < 0.10        
where 𝜋𝐶 =  0.80 and 𝜋𝑇 =  0.70 under the null and 𝜋𝐶 = 𝜋𝑇 =  0.80 under the 
alternative.   This yielded a 𝛽1under the null of -0.539 and under the alternative a 
value of zero. An odds ratio of 0.583 was derived from the expected probability of 
success in each of the two groups, which served as the cutoff for claiming non-
inferiority. The values of 𝛽2 and 𝛽0 remained similar to the superiority setting.  
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The total sample size was estimated as 𝑁=676, so that the power to detect a 
treatment difference when 𝛽2 = 0 was again 80%. 
 It should be noted that results on the linear/risk difference scale are not 
necessarily immediately applicable to the logistic/odds ratio scale but may require 
translation. The authors present hypotheses and parameters in terms of the linear 
scale to facilitate communication with clinical investigators but then analyze 
results using logistic regression to avoid convergence issues that would otherwise 
arise in the tails of the nonlinear distribution.
26
  It is also noteworthy that sample 
size has to be increased slightly when the effect size is translated from a risk 
difference to an odds ratio.
20
 
 
3.3b Simulation Strategy 
 The simulated subject dataset is filled sequentially by first assigning the 
level of covariate (0 or 1), based on dichotomization of a random uniform 
distribution, and then a treatment indicator via either complete randomization, 
where the probability that the i
th
 patient is assigned to treatment (pi,trt) is 0.5, or 
permuted block randomization within each level of the covariate according to the 
following: 
𝑝𝑖,𝑡𝑟𝑡 = 
(𝑏 2⁄ )(1 + 𝑖𝑛𝑡 (
(𝑖 − 1)
𝑏
⁄ )) − 𝑛𝑖−1,𝑡𝑟𝑡
𝑏 (1 − 𝑖𝑛𝑡 (
(𝑖 − 1)
𝑏
⁄ )) − (𝑖 − 1)
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where i = subject, b = block size, int = next highest integer value, and ni-1 = 
number previously assigned to treatment. A block size of six was chosen as a 
compromise between the authors’ beliefs about current popular practice and the 
desire for results to be comparable to those of Kahan and  Morris
23
, who used a 
block size of eight. The probability of success for each patient is assigned as 
follows: 
 𝑝𝑖,   𝑠𝑢𝑐𝑐𝑒𝑠𝑠 =
exp (𝛽1𝑇𝑟𝑡 + 𝛽2𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒)
1 + exp (𝛽1𝑇𝑟𝑡 + 𝛽2𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒)
 
and again compared to a random uniform distribution for dichotomization.  Once 
the subject table is populated, unadjusted and adjusted analyses are conducted, 
and estimates of the odds ratios of the treatment effect, as well as their standard 
errors and two-sided 95% confidence intervals are extracted.   
Power, defined as the percentage of trials under the alternative hypothesis 
in which the lower bound of the confidence interval for the odds ratio crosses the 
pre-determined margin (>1.0 for superiority or >0.583 for non-inferiority), as well 
as type I error, defined as the percentage of trials under the null in which the 
lower bound of the confidence interval for the odds ratio crosses the pre-
determined margin, are calculated across 10,000 iterations.  Bias in the estimate 
of the treatment effect, defined as the average difference between the estimate and 
the true value of 𝛽1, and bias in the standard error of the estimate of treatment 
effect, defined as the mean difference between empirical and model standard 
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errors, are calculated under the alternative hypothesis in the context of superiority 
and under the null hypothesis in the context of non-inferiority, as this is where 
one would expect to find a treatment difference. 
 
3.4 Simulation Results 
3.4a Superiority 
In the context of superiority, there is a slight loss in power as 𝛽2 (which 
represents the strength of the covariate) moves away from zero in either direction 
for unadjusted analyses and a slight gain in power for adjusted analyses. 
Furthermore, there appears to be little impact of balancing at randomization 
among adjusted analyses, but some improvement of covariate adjusted permuted 
block randomization over complete randomization among unadjusted analyses.  
Type I error, under all scenarios, yields close to nominal values regardless of the 
value for 𝛽2, with the exception of the scenario that employed covariate adjusted 
permuted block randomization coupled with an unadjusted analysis.  In this 
scenario, type I error decreased as 𝛽2 moved away from zero in either direction.   
Under the alternative hypothesis, we can see that the unadjusted analyses’ 
treatment effects and standard errors underestimate those of the adjusted analyses.  
Furthermore, the bias in the standard error appears to be less severe for covariate 
adjusted permuted block randomization than for complete randomization due to 
the correlation it creates between treatment groups.  However, the treatment 
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estimate, as well as its accompanying standard error, is nearly unbiased (a slight 
positive bias was detected, but determined to be minimal) in adjusted analyses, 
with negligible effect of covariate balancing at randomization. 
 
Figure 3.4a.1 Operating Characteristics for Covariate Adjustment in Superiority 
Trials 
 
3.4b Non-Inferiority 
The operating characteristics in the context of non-inferiority are quite 
different from superiority.  In this setting, power decreases slightly as 𝛽2 moves 
away from zero in either direction for adjusted analyses, and type I error is nearly 
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maintained regardless of covariate balancing at randomization via permuted 
block.  For unadjusted analyses, an opposite effect from that demonstrated in the 
context of unadjusted analyses in superiority is observed.  Power and type I error 
is increased as 𝛽2  moves away from zero in either direction.  This increase in 
type I error for unadjusted analyses in the presence of an influential prognostic 
covariate is greater in complete randomization than in the context of covariate 
adjusted permuted block randomization.  Type I error rates are nearly maintained 
for adjusted analyses regardless of balancing at randomization.   
 The treatment estimate and its standard error are unbiased for adjusted 
analyses, whereas the treatment estimate is biased upward toward zero for 
unadjusted analyses regardless of balancing at randomization via permuted block.  
The standard error of this estimate follows the same pattern as the alternative 
hypothesis in the superiority setting (namely, standard errors are deflated for 
unadjusted analyses with covariate adjusted permuted block randomization 
yielding a less pronounced effect). 
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Figure 3.4b.1 Operating Characteristics for Covariate Adjustment in Non-
Inferiority Trials 
 
3.5 Discussion 
The results presented above demonstrate that adjustment for important 
prognostic covariates in analysis is always preferred, regardless of whether the 
hypothesis to be tested is one of superiority or non-inferiority.  In a superiority 
setting, adjusted analyses yield greater power to detect a treatment difference as 
compared to unadjusted analyses, as well as nominal type I error. In a non-
inferiority setting, adjusted analyses do not have the added benefit of increased 
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power but are protective against unacceptable increases in type I error.  
Furthermore, adjusted analyses yield nearly unbiased estimates of treatment effect 
in both scenarios and biases in standard error that seem unavoidable given the 
nature of the nonlinear relationship between outcome and predictors.   
These findings expand upon those of Garrett
18
 by further quantifying the 
impact of failure to adjust for important prognostic covariates in terms of bias in 
the treatment estimate and subsequent implications for power and type I error.  It 
also provides noteworthy extensions in terms of the evaluation of different 
covariate adjustment strategies (i.e., randomization versus analysis), a direct 
comparison with a superiority design, and the extendibility of such findings to 
different specifications of parameters.  For example, in addition to the strength of 
association between covariate and outcome, the probability of success in the 
control also plays a role in the variance of the treatment estimate such that 
different starting points do not translate to equivalent odds ratios. Thus, an 
absolute non-inferiority margin of 0.10, which we set in the non-inferiority 
setting, does not always translate to a relative non-inferiority margin of 0.583, but 
only given an assumed probability of success in the control of 80%.  To 
demonstrate the sensitivity of findings, a second simulation was undertaken in 
which the absolute non-inferiority margin remained 0.10, but the probabilities of 
success were changed to 𝜋𝐶 = 0.55 and 𝜋𝑇 = 0.45 (which translates to a relative 
non-inferiority margin of 0.669). In this scenario, the overall variability is 
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increased and the impact of failure to adjust for covariates is magnified, but 
similar trends were observed in all operating characteristics for the non-inferiority 
setting.   
A limitation of this work lies in the fact that the observed differences 
between unadjusted and adjusted analyses can be thought of in terms of model 
inconsistency. The adjusted model is a conditional, or subject specific model, 
whereas the unadjusted model is a marginal, or population averaged, model.  
Thus, one could argue that the bias illustrated in the unadjusted treatment effect 
estimates is actually just a result of the difference between the two modeling 
strategies.
24,37
 While this is worth comment, the simulation results, as presented, 
retain their practical value as an explanation of the impact of covariate 
adjustment. 
 Finally, the current research suggests that, in the context of adjusted 
analyses of binary outcomes, covariate adjusted permuted block randomization 
may not provide much gain over complete randomization.  In fact, there were 
only minimal effects of balancing at randomization in the context of adjusted 
analyses for any of the operating characteristics that were presented, a result that 
was maintained even under a scenario in which a significant 70/30 covariate 
imbalance was forced (simulation not shown).  In addition, the use of covariate 
adjusted permuted block randomization results in a loss of randomness via an 
increase in the number of deterministic assignments.
44
   However, further research 
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is required to determine whether these findings can be generalized to other 
randomization schemes.   
 This research illustrates the impact of covariate adjustment at 
randomization and analysis in non-inferiority trials with binary outcomes and 
demonstrates the importance of conducting adjusted analyses in the presence of 
important prognostic covariates. Although we have exaggerated the covariate 
effect (i.e., 𝛽2), this was done for purely theoretical purposes. In practice, it is 
unlikely that one would see a covariate effect of +/- 3.0 and the resulting type I 
error rate of 0.175. Regardless, our results hold as we see an inflation in the type I 
error when the covariate is not equal to 0; for example, a more practical case of a 
covariate effect of +/- 1.5 shows a type I error rate of 0.045. This suggests that 
proper adjustment will result in unbiased estimates of treatment and reduce the 
probability of committing a type I error, which is of particular importance in non-
inferiority trials, as claiming non-inferiority when it is false may have severe 
implications for patients. 
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Chapter 4 
Aim 2: 
Choosing Covariates for Adjustment in Non-Inferiority Trials 
with Binary Outcomes Based on Influence and Disparity 
  
 It has been shown that the type I error rate is inflated when important 
covariates are excluded from a non-inferiority analysis.
18,27
 Traditionally, whether 
to adjust for a covariate in a model is based solely on statistical significance or 
some other criteria such as Akaike information criterion (AIC) that relates to the 
magnitude of the effect on outcome.  In addition, some select based on tests of 
baseline imbalance. However, several authors suggest that these aspects be 
considered simultaneously.  Canner
6
 developed a statistic for binary outcomes to 
determine the relative importance of including a covariate in a model based on 
both its effect on outcome and its association with treatment.  Although Canner’s 
approach assumed no treatment effect, Beach and Meier
3
 extended this to non-
zero treatment effects in the context of linear regression. The current research 
combines the methods of Canner for binary outcomes with the methods of Beach 
and Meier for non-zero treatment effect in order to quantify the relative 
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importance of including covariates in a non-inferiority study with a binary 
outcome. Theoretical results are presented and applied via simulation. 
 
4.1 Introduction  
 In observational studies, the goal of covariate adjustment is often to 
quantify the impact of various baseline factors on outcome in order to understand 
the predictors of disease.  In large randomized clinical trials, the goal becomes the 
unbiased and precise estimation of a treatment’s effect on outcome.  A truly 
unbiased estimate of treatment effect results from adjustment for any covariate 
with even a slight impact on outcome.  As this is, of course, impossible in 
practice, a method of choosing the most important subset of potential covariates is 
of value.  
 If the goal is to obtain an accurate and unbiased estimate of the treatment 
effect, then one should choose a subset of covariates based on their association 
with outcome.  This can be done via tests of bivariate association in which any 
covariate reaching statistical significance is included in the model for outcome. 
Alternatively, stepwise selection procedures which consider the iterative addition 
or removal of a single, or subset, of covariates can be employed, and decisions 
can be based on p-values, AIC, or some other criteria of influence. For binary 
outcomes, accuracy and precision represent competing goals; as the number of 
covariates in the model increases, the accuracy of the point estimate will also 
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increase, but the precision will decrease given the non-linear nature of the 
relationship with outcome.   
  If precision of the treatment estimate is the goal, then one should choose 
covariates based on the disparity with treatment allocation rather than association 
with outcome.  Some trialists do not consider this issue in the formation of the 
model, but rather trust that the randomization scheme has controlled for any 
chance imbalances.
1
 Others choose to test this formally with two-sample tests for 
baseline imbalance and then adjust for those covariates reaching statistical 
significance.  While this practice has been condemned in much of the regulatory 
and statistical literature due to its impact on type I error,
 22,36 
it remains popular 
and is often reported in the first table of many manuscripts.  
 Perhaps, a better approach for choosing covariates would consider both 
influence on outcome and disparity with treatment.  In a presentation to the 
Society for Clinical Trials in 1981, Canner
6
 developed a statistic to do this 
simultaneously for binary outcomes with no treatment effect, which Beach and 
Meier
3
 later extended for continuous outcomes with non-zero treatment effect. 
The current research seeks to expand Canner and Beach and Meier’s work for 
application to a non-inferiority design with a binary outcome.   
 A typical superiority design generally seeks to show that a new drug is 
superior to placebo by some predetermined amount.  A non-inferiority study, 
however, is often used when previous studies have established superiority of a 
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therapy, but a new therapy may offer some additional benefit such as lower cost, 
greater ease of administration, or fewer side effects. In this case, if the new drug is 
equally, or even slightly less, efficacious than the current standard of care, it 
would likely be of clinical benefit.  Thus, the non-inferiority design seeks to 
answer the question of “no worse than” by some amount, the non-inferiority 
margin (𝑑), that would be deemed an acceptable loss given the benefit tradeoff. 
This reversal of hypotheses leads to a reversal in the implications of type I and 
type II error.
5
 As such, biased and imprecise estimates of treatment effect in non-
inferiority studies can increase the likelihood of rejecting the null hypothesis and 
claiming non-inferiority.  Thus, there is often a non-trivial inflation of the type I 
error probability when analyses fail to account for important covariates.
18,27
  
Given this important difference, there is potential for an extension of Canner and 
Beach and Meier’s joint statistic for influence and disparity for use in 
identification of important covariates requiring adjustment in non-inferiority 
trials. Section 4.2 reviews the existing literature.  Section 4.3 presents a 
theoretical argument for the inclusion of the non-inferiority margin in the statistic, 
followed by a simulation study in Sections 4.4 through 4.6, advice for practical 
use in Section 4.7, and discussion in Section 4.8 . 
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4.2 Existing Literature 
 Canner
6
 presented a method to quantify the impact of adjustment for a 
binary covariate given a binary outcome and no treatment effect that was based on 
both disparity (i.e., imbalance between treatment arms) and influence on outcome.  
In 1989, Beach and Meier
3
 expanded upon Canner’s result to include a non-zero 
treatment effect. They presented the following condensed 2x2x2 table, in which 
the columns corresponding to the number of successes for each combination of 
treatment and covariate have been removed. 
 Let 𝑁 be the number per treatment arm, 𝑝 be the overall proportion of 
failure, and 𝑟1be the correlation between treatment (𝑋1) and covariate (𝑋2). 𝑟2 
quantifies the strength of the association between covariate (𝑋2)  and outcome (𝑌) 
and can be derived as follows: 
𝑟2 =
𝑐𝑜𝑟𝑟(𝑋2, 𝑌)√𝑝(1 − 𝑝)
𝑝
 
The number in each cell of Table 4.2.1 can be obtained by multiplying the 
proportion of failures (first expression) by the total number of individuals (second 
expression). Thus, for the first cell, which represents the number without the 
covariate in the control arm, there are 𝑝(1 − 𝑟2) ∗ 𝑁(1 +  𝑟1)/2 individuals. 
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Table 4.2.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate  
  Without 
Covariate 
With  
Covariate 
 Total 
Control 
Arm 
𝑝(1 − 𝑟2) 
𝑁(1 +  𝑟1)/2 
𝑝(1 + 𝑟2) 
𝑁(1 −  𝑟1)/2 
𝑝(1 − 𝑟1𝑟2) 
𝑁 
Treatment 
Arm 
𝑝(1 − 𝑟2) 
𝑁(1 −  𝑟1)/2 
𝑝(1 + 𝑟2) 
𝑁(1 +  𝑟1)/2 
𝑝(1 + 𝑟1𝑟2) 
𝑁 
 Total 𝑝(1 − 𝑟2) 
𝑁 
𝑝(1 + 𝑟2) 
𝑁 
𝑝 
2𝑁 
 
 From this, Canner developed an “influence” statistic for the distribution of 
covariate across outcome (𝑍𝐼) and a “disparity” statistic for the distribution of 
covariate across treatment arms (𝑍𝐷):  
𝑍𝐼 =
𝑝(1 + 𝑟2) − 𝑝(1 − 𝑟2)
√2𝑝𝑞/𝑁
=
√2𝑁𝑝𝑟2
√𝑝𝑞
 
𝑍𝐷 =
[(
𝑁
2)
(1 + 𝑟1) − (
𝑁
2) (1 − 𝑟1)]√2𝑁
√𝑁2
=  √2𝑁𝑟1 
where 𝑞 = 1 − 𝑝. The statistic for the unadjusted treatment effect (𝑍𝑈) is: 
𝑍𝑈 =
𝑝(1 + 𝑟1𝑟2) − 𝑝(1 − 𝑟1𝑟2)
√2𝑝𝑞/𝑁
=  
√2𝑁𝑝𝑟1𝑟2
√𝑝𝑞
 
and the adjusted treatment effect is equal to zero (𝑍𝐴 = 0) by construction 
because the treatment effect is equal to zero. Thus, it follows that the difference 
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between the unadjusted and adjusted statistics is the product of the statistics for 
influence and disparity: 
𝑍𝑈 − 𝑍𝐴 = 𝑍𝑈 =
√2𝑁𝑝𝑟1𝑟2
√𝑝𝑞
=
(
√2𝑁𝑝𝑟2
√𝑝𝑞
)√2𝑁𝑟1
√2𝑁
=
𝑍𝐼𝑍𝐷
√2𝑁
 
This result can fully quantify the impact of failing to adjust for a covariate when 
there is no treatment effect.  However, when a treatment effect is present, 𝑍𝐴 is no 
longer equal to zero.  Beach and Meier extended Canner’s method to present 
similar findings for a non-zero treatment effect in the context of linear regression 
parameters, which Canner
7
 then re-derived in terms of correlations.  
 Canner presented the adjusted treatment effect as: 
𝑍𝐴 =
𝑏𝑦1.2
√𝑣𝑎𝑟𝑏𝑦1.2̂
=
𝑟𝑦1.2√𝑁 − 3
√1 − 𝑟𝑦1.2
2
 
where 𝑏𝑦1.2 is the partial regression coefficient for outcome (𝑌) and treatment 
(𝑋1) given covariate (𝑋2) and 𝑟𝑦1.2 is the partial correlation coefficient for 
outcome (𝑌) and treatment (𝑋1) given covariate (𝑋2). It can also be shown that:  
𝑍𝐴 =
(𝑟𝑦1 − 𝑟𝑦2𝑟12√𝑁 − 3)
√1 − 𝑟𝑦1
2 − 𝑟𝑦2
2 − 𝑟12
2 + 2𝑟𝑦1𝑟𝑦2𝑟12
 
given the well-known relationship: 
𝑟𝑦1.2 =
𝑟𝑦1 − 𝑟𝑦2𝑟12
√(1 − 𝑟𝑦2
2 )(1 − 𝑟12
2 )
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where 𝑟𝑦1 is the correlation between outcome (𝑌) and treatment (𝑋1), 𝑟𝑦2 is the 
correlation between outcome (𝑌) and covariate (𝑋2), and 𝑟12 is the correlation 
between treatment (𝑋1) and covariate (𝑋2).  This expression for 𝑍𝐴 can be used in 
conjunction with previous results to evaluate the impact of adjustment for a 
covariate when the treatment effect is non-zero. 
 
4.3 Extension to Non-Inferiority Setting 
 The notation and results of Canner
6,7
 and Beach and Meier
3
 can be 
extended to develop an expression for the impact of adjustment for a covariate in 
the non-inferiority setting.  In this scenario, the assumed treatment effect is non-
zero and equal to the non-inferiority margin (𝑑). The condensed 2x2x2 table can 
be written as: 
 
Table 4.3.1 Condensed 2x2x2 Table of Outcome, Treatment, and Covariate with 
Treatment Effect Equal to Non-Inferiority Margin (𝑑) 
 
 Without Covariate With Covariate Total 
Control 
Arm 
𝑝(1 − 𝑟2) 
𝑁(1 +  𝑟1)/2 
𝑝(1 + 𝑟2) 
𝑁(1 −  𝑟1)/2 
𝑝(1 − 𝑟1𝑟2) 
𝑁 
Treatment 
Arm 
(𝑝 + 𝑑)(1 − 𝑟2) 
𝑁(1 −  𝑟1)/2 
(𝑝 + 𝑑)(1 + 𝑟2) 
𝑁(1 +  𝑟1)/2 
(𝑝 + 𝑑)(1 + 𝑟1𝑟2) 
𝑁 
Total (1/2)(2𝑝 + 𝑑(1 − 𝑟1))(1 − 𝑟2) 
𝑁 
(1/2)(2𝑝 + 𝑑(1 + 𝑟1))(1 + 𝑟2) 
𝑁 
(1/2)(2𝑝 + 𝑑(1 + 𝑟1𝑟2)) 
2𝑁 
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In this case, the new expression for the association between covariate and 
outcome is:  
𝑟2
∗ =
𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√
2𝑝 + 𝑑
2 (1 −
2𝑝 + 𝑑
2 )
2𝑝 + 𝑑
2
 
From this, a new expression for influence (𝑍𝐼∗) is derived from the marginals as 
before: 
𝑍𝐼∗ =
(
1
2
) (2𝑝 + 𝑑(1 + 𝑟1))(1 + 𝑟2
∗) − (
1
2
) (2𝑝 + 𝑑(1 − 𝑟1))(1 − 𝑟2
∗)
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁
 
𝑍𝐼∗ = 
2𝑝𝑟2
∗ + 𝑑(𝑟1 + 𝑟2
∗)
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁
 
Canner’s unadjusted statistic can then be re-written to include this: 
𝑍𝐶∗ =
𝑍𝐼∗  𝑍𝐷
√2𝑁
  
and combined with the adjusted statistic as follows: 
𝑍𝐶∗ − 𝑍𝐴 =
𝑍𝐼∗  𝑍𝐷
√2𝑁
 − 
(𝑟𝑦1 − 𝑟𝑦2𝑟12)√2𝑁 − 3)
√1 − 𝑟𝑦1
2 − 𝑟𝑦2
2 − 𝑟12
2 + 2𝑟𝑦1𝑟𝑦2𝑟12
 
where the correlation between outcome and treatment (𝑟𝑦1), the correlation 
between outcome and covariate (𝑟𝑦2), and the correlation between treatment and 
covariate (𝑟12) are now equal to
28
:  
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𝑟𝑦1 =
𝑝𝑟1𝑟2
∗ + (
1
2
)𝑑 + (
1
2
)𝑑𝑟1𝑟2
∗
√𝑝 + (
1
2
) 𝑑 + (
1
2
) 𝑑𝑟1𝑟2
∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1𝑟2
∗ − (
1
4
) 𝑑2 − (
1
2
) 𝑑2𝑟1𝑟2
∗ − (
1
4
) 𝑑2𝑟1
2𝑟2
∗2
 
𝑟𝑦2 =
(
1
2
)𝑑𝑟1 + (
1
2
) 𝑑𝑟2
∗ + 𝑝𝑟2
∗
√𝑝 + (
1
2
) 𝑑 + (
1
2
)𝑑𝑟1𝑟2
∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1𝑟2
∗ − (
1
4
) 𝑑2 − (
1
2
) 𝑑2𝑟1𝑟2
∗ − (
1
4
)𝑑2𝑟1
2𝑟2
∗2
 
𝑟12 = 𝑟1 
This new statistic (𝑍𝐶∗ − 𝑍𝐴) can be used to evaluate the importance of 
adjustment for one covariate over another in a non-inferiority setting. 
 
4.4 Relative Importance of 𝒓𝟏 and 𝒓𝟐 
 To evaluate the impact of varying scenarios on this statistic for importance 
(𝑍𝐶∗ − 𝑍𝐴) in a non-inferiority setting, a simulation study was undertaken.  The 
simulation explored this statistic’s behavior when subject to changes in 𝑟1 and 𝑟2 
for given proportions of failure (or success) (𝑝) and non-inferiority margins (𝑑). 
Figure 4.4.1 illustrates the impact of 𝑟1 and 𝑟2 when p is 0.4, d is 0.1, and 𝑟1 and 𝑟2 
are varied from -0.9 to 0.9. In this scenario, 𝑁 is set to be 388 per arm to ensure 
80% power.  
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Figure 4.4.1 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 
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The statistic for the importance of adjustment is presented as the contour and 
ranges from -20.35 to 20.30. The green represents values of the statistic close 
to −𝑍𝐴, which occur when either 𝑟1or 𝑟2are close to zero. The point (𝑟1, 𝑟2) =
(0,0) occurs at the center of both the three dimensional and contour plots. The 
yellow and beige represent increasingly positive values of the statistic, which 
occur when 𝑟1 and 𝑟2 are in the same direction (i.e., both positive or both 
negative); blue and purple represent increasingly negative values of the statistic, 
which occur when 𝑟1 and 𝑟2 are in opposite directions (i.e., one positive and one 
negative). Furthermore, a near symmetry exists such that similar values of the 
statistic are obtained when 𝑟1 is positive and 𝑟2 is negative as when 𝑟1 is negative 
and 𝑟2 is positive, and the same is true for associations in the same direction. 
 We can see that according to our statistic, evaluation of either imbalance 
(𝑟1) or strength of association (𝑟2) in isolation is not sufficient to identify the most 
important subset of covariates. Rather, adjustment is necessary when a covariate 
is both imbalanced and strongly associated with outcome, and these two forces 
are given similar weight. We will now narrow our focus to more practical values 
(i.e., where 𝑟1 and 𝑟2 range from -0.2 to 0.2) to explore the relative importance of 
these two factors. 
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Figure 4.4.2 ZC*-ZA for Reduced Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 =
0.1 
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Given this reduced range, it becomes apparent that even for moderate strengths of 
association (i.e., 𝑟1 and 𝑟2  between -0.2 and 0.2) the statistic is close to −𝑍𝐴 and 
adjustment is not necessary. However, when either 𝑟1 or 𝑟2 is large and the other 
is non-negligible, adjustment is necessary. Such findings are consistent with 
previous research on covariate adjustment in the presence of imbalance.
1,3,8,29,31,36
 
 In addition, it is important to note that while the magnitude of the statistic 
is dependent on the sample size and probability of failure, the relative importance 
given to 𝑟1 and 𝑟2 remains generally consistent. For example, Figure 4.4.3 shows 
the statistic when 𝑝 is 0.1 (𝑁 is set to be 199 to maintain the same power as 
above). With the probability of failure in the standard of care now equal to the 
treatment effect (i.e., the non-inferiority margin), the impact of the treatment 
effect is more apparent. The range of the statistic is reduced and, while the shape 
remains similar, the asymmetry is more pronounced.  
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Figure 4.4.3 ZC*-Z A for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 199, 𝑝 = 0.1, 𝑑 = 0.1 
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4.5 Relationship to Bias  
 The proposed statistic also has an important relationship to the bias in the 
estimate of the treatment effect on the risk difference scale.  The bias in the 
original case where 𝑝 is 0.4, 𝑑 is 0.1, and 𝑁 is 388 is presented below as the 
unadjusted estimate minus the adjusted estimate (𝛽𝑢𝑛𝑎𝑑𝑗 − 𝛽𝑎𝑑𝑗). 
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Figure 4.5.1 Bias for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 
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From the comparison of Figure 4.5.1 to Figure 4.4.1, one can see that the statistic 
for importance of adjustment maps nicely to the bias in the treatment estimate. 
Given 𝑟1 and 𝑟2  equal to zero, the statistic is equal to −𝑍𝐴 and the estimate of the 
treatment effect is unbiased. When 𝑟1 and 𝑟2  are in the same direction (i.e., both 
positive or both negative), the unadjusted estimate is biased upward, and when 𝑟1 
and 𝑟2 oppose each other (i.e., one is positive and the other is negative), the 
unadjusted estimate is biased downward.  In the case of a two-sided test, this is an 
unimportant distinction.  However, in the context of non-inferiority, a one-sided 
test (or confidence interval) is used, and this directionality becomes important.  
 
4.6 Implications for Error 
 Adjustment for covariates will always slightly increase the width of the 
confidence interval of the treatment effect in the context of logistic regression, 
and the degree to which it changes is primarily dependent on the magnitude (but 
not the directionality) of 𝑟1.
33
 However, as shown in Figure 4.6.1, this increase 
only becomes important at extreme values of 𝑟1 and 𝑟2.  
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Figure 4.6.1 Change in Width of the 95% Confidence Interval (Unadjusted – 
Adjusted) for Full Range of 𝑟1 and 𝑟2 when 𝑁 = 388, 𝑝 = 0.4, 𝑑 = 0.1 
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 If one is concerned about whether the non-inferiority margin is crossed, as 
in the case of a confidence interval approach to a non-inferiority hypothesis, both 
the point estimate and its variance must be considered.  As in the theoretical 
schematic presented in Figure 4.6.2, while the increased variance imposed by 
adjustment may push the upper bound beyond the margin, decreasing the potential 
to reject the null hypothesis of inferiority, this impact is small in comparison to 
the change in the estimate itself.  Thus, there is a serious potential for committing 
a type I error when failing to adjust for a covariate that has imbalance and 
influence in the same direction, regardless of whether that direction is positive or 
negative. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.2 Movement of the 95% Confidence Interval Given Adjustment and 
Implications for Error Probabilities in Non-Inferiority Trials 
−𝑑 𝑑 
Fail to Reject 
when Modeling 
Probability of 
Success  
(tx inferior) 
Fail to Reject 
when Modeling 
Probability of 
Failure  
(tx inferior) 
Reject 
(tx non-inferior) 
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4.7 Practical Use 
  In practice, the statistic for importance of adjustment can be used as a 
diagnostic tool. To this end, one might calculate values of the statistic for all 
available covariates and then rank them.  The covariate corresponding to the 
largest value would be the most important covariate for which to adjust and so on.  
For illustrative purposes, consider a plot of covariates corresponding to all 
possible combinations for 𝑟1and 𝑟2 with 𝑁, 𝑝, and 𝑑 again equal to 388, 0.4, and 
0.1, respectively. 
 
Figure 4.7.1: Ranking of Covariates with All Possible Combinations of Full 
Range of 𝑟1and 𝑟2 where 𝑁 = 388, 𝑝 = 0.4, and 𝑑 = 0.1 
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In a real trial setting, it is likely that there will be less than ten covariates under 
consideration.  Thus, random subsets are presented: 
 
Figure 4.7.2: Random Subsets of Ten Covariates from Figure 4.7.1 
 
Generally, one would expect to see an “elbow” or plateau which could be used as 
the cut point for adjustment. In so doing, one can choose to include only those 
covariates falling above the cut point in the final analysis model.  Such 
simultaneous consideration of both influence and disparity allows a trialist to find 
the optimal balance between the competing goals of modeling a treatment effect 
that is both precise and conservative. 
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4.8. Discussion 
 It has been shown that failure to adjust for covariates in a non-inferiority 
trial with binary outcomes leads to biased estimates of the treatment effect and 
increased type I error.
18,27
 As such, the issue becomes not whether one should 
adjust, but rather which covariates should be included. While many model 
selection procedures are theoretically akin to the statistic for influence and tests of 
baseline imbalance are theoretically akin to the statistic for disparity, neither 
approach considers these effects simultaneously.  The proposed statistic allows 
for evaluation of the importance of adjustment for each covariate relative to the 
others and, when used properly, should result in a better estimate of treatment 
effect in terms conservativeness and precision given the available data.  
  The authors recognize that, like tests of baseline imbalance and other 
data-driven approaches to covariate adjustment, the use of this statistic may have 
important implications for type I error that should be further quantified in a 
multivariate setting.  Berger
4
 has proposed an extension whereby the disparity of 
a candidate covariate is calculated as the weighted average of the disparities 
within each group formed by the covariates already present in the model. The 
practical use of this approach, however, is difficult to explore.  The lack of 
information present in binary variables leads to highly variable results such that 
iterative methods may not be sufficient to assure consistency. Thus, while this has 
been evaluated in the context of linear regression
3
, it remains largely unexplored 
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in the context of binary outcomes.  Still, the proposed statistic remains useful as a 
diagnostic tool when used in conjunction with other techniques for covariate 
selection. 
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Chapter 5 
Aim 3:  
Application of a Joint Statistic for Influence and Disparity in the 
Identification of Baseline Covariates Required In Analysis of Non-
Inferiority Trials  
 
 Due to the increase in type I error imposed by exclusion of important 
prognostic variables in non-inferiority trials, a joint statistic for the importance of 
adjusting for a given covariate based on its association with outcome (influence) 
and its association with treatment (imbalance) has been developed for use when 
important factors are not known a priori. Once the data has been collected, this 
statistic can be used to rank the relative importance of adjusting for one covariate 
over another, and its distribution can be used to determine the optimal number of 
covariates to include in analysis.  The goal of the present work is to evaluate the 
practicality of this method of covariate selection in the rapid anti-convulsant 
medication prior to arrival trial (RAMPART) in terms of changes to treatment 
estimates and possible implications for maintenance of type I error.        
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5.1 Introduction 
 The ICH guidelines
22
 for the use of baseline covariates in clinical trials 
states:  
 “Pre-trial deliberations should identify those covariates and factors 
 expected to have an important influence on the primary variable(s), and 
 should consider how to account for these in the analysis in order to 
 improve precision and to compensate for any lack of balance between 
 treatment groups. If one or more factors are used to stratify the design, it is 
 appropriate to account for those factors in the analysis. When the potential 
 value of an adjustment is in doubt, it is often advisable to nominate the 
 unadjusted analysis as the one for primary attention, the adjusted analysis 
 being supportive.” 
 
Thus, according to this guidance, covariates should be specified a priori and those 
that are deemed necessary for inclusion should be present in both the 
randomization and the analysis. However, potential prognostic factors are not 
always known at the start of a trial. Although adjusted analyses offer more power 
to detect a treatment difference in superiority trials
15-17,26,33
, unadjusted analyses 
may not necessarily inflate type I error. This does not hold for non-inferiority 
designs.  
 In non-inferiority trials, unadjusted analyses can be plagued by sometimes 
dramatic increases in type I error in the presence of important prognostic 
variables.  According to the author’s previous work
27
, these rates can be doubled 
depending on the sample size, the probability of success in the standard of care 
group, the underlying treatment difference, and the covariate’s strength of 
association with outcome. Thus, it is necessary to develop an approach to identify 
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important prognostic covariates in non-inferiority trials where such factors are not 
known a priori.  Although much of the statistical literature condemns the use of 
data-driven approaches in clinical trials due to the increased probability of 
selection bias,
1,4.31,32,35,36 
such work has been done in the context of the superiority 
design and has not been fully investigated in non-inferiority trials.   
 The two factors contributing to the impact of a covariate on the estimate of 
the treatment effect are its association with treatment assignment (i.e., imbalance) 
and its association with outcome.  If precision is the goal, then a trialist should 
adjust for those baseline covariates that are imbalanced across treatment groups, 
but if accuracy is the goal, then those covariates that are associated with outcome, 
regardless of imbalance, should be included.
3,7,32 
As Canner
7
 has illustrated, to 
obtain a treatment estimate that is both precise and accurate, these factors must be 
considered in tandem. Thus, a joint statistic has been developed to evaluate these 
aspects simultaneously for a given covariate in a trial with dichotomous outcome 
and has been subsequently extended for use in the non-inferiority setting.
28
  The 
aim of the current research is to evaluate the use of this joint statistic in a practical 
clinical trial application.   
 
5.2 Existing Literature 
 It has been shown that failure to adjust for covariates in a non-inferiority 
trial with a non-linear outcome leads to biased estimates of the treatment effect 
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and increased type I error.
18,27
  As such, the issue becomes not whether one should 
adjust, but rather which covariates should be considered for inclusion in the 
analysis. While many model selection procedures are theoretically akin to the 
statistic for influence and tests of baseline imbalance are theoretically akin to the 
statistic for disparity, neither approach considers these effects simultaneously.  
Canner
6
 developed a statistic to quantify a covariate’s disparity and influence 
given a binary outcome and zero treatment effect, which Beach and Meier
3
 
extended for non-zero treatment effects with continuous outcome. In the author’s 
previous paper
28
, Canner and Beach and Meier’s work were used to develop a 
statistic for the non-inferiority framework with binary outcome and non-null 
treatment effect.  This statistic, which represents the product of statistics for a 
covariate’s influence on outcome (𝑍𝐼
∗) and disparity across treatment groups (𝑍𝐷), 
can be expressed as follows: 
𝑍𝐶∗ − 𝑍𝐴 =
𝑍𝐼∗  𝑍𝐷
√2𝑁
 − 
(𝑟𝑦1 − 𝑟𝑦2𝑟12)√2𝑁 − 3)
√1 − 𝑟𝑦1
2 − 𝑟𝑦2
2 − 𝑟12
2 + 2𝑟𝑦1𝑟𝑦2𝑟12
 
where 
𝑍𝐼∗ = 
2𝑝𝑟2
∗ + 𝑑(𝑟1 + 𝑟2
∗)
√𝑝𝑞 + (𝑝 + 𝑑)(1 − (𝑝 + 𝑑))
𝑁
 
𝑍𝐷 =
[(
𝑁
2)
(1 + 𝑟1) − (
𝑁
2)(1 − 𝑟1)]√2𝑁
√𝑁2
=  √2𝑁𝑟1 
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𝑟1 = 𝑟12 = 𝑐𝑜𝑟𝑟(𝑡𝑟𝑡, 𝑐𝑜𝑣) 
𝑟2
∗ =
𝑐𝑜𝑟𝑟(𝑐𝑜𝑣, 𝑜𝑢𝑡)√
2𝑝 + 𝑑
2 (1 −
2𝑝 + 𝑑
2 )
2𝑝 + 𝑑
2
 
𝑟𝑦1 =
𝑝𝑟1𝑟2
∗ + (
1
2
)𝑑 + (
1
2
)𝑑𝑟1𝑟2
∗
√𝑝 + (
1
2
) 𝑑 + (
1
2
) 𝑑𝑟1𝑟2
∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1𝑟2
∗ − (
1
4
) 𝑑2 − (
1
2
) 𝑑2𝑟1𝑟2
∗ − (
1
4
) 𝑑2𝑟1
2𝑟2
∗2
 
𝑟𝑦2 =
(
1
2
)𝑑𝑟1 + (
1
2
) 𝑑𝑟2
∗ + 𝑝𝑟2
∗
√𝑝 + (
1
2
) 𝑑 + (
1
2
)𝑑𝑟1𝑟2
∗ − 𝑝2 − 𝑝𝑑 − 𝑝𝑑𝑟1𝑟2
∗ − (
1
4
) 𝑑2 − (
1
2
) 𝑑2𝑟1𝑟2
∗ − (
1
4
)𝑑2𝑟1
2𝑟2
∗2
 
𝑁 = 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑖𝑧𝑒 𝑝𝑒𝑟 𝑎𝑟𝑚 
𝑝 = 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑓𝑎𝑖𝑙𝑢𝑟𝑒 
𝑑 = 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑒𝑐𝑡 
By calculating this statistic for all available covariates in the study data and 
ranking, a trialist can evaluate the importance of adjusting for one covariate over 
another in a non-inferiority setting. The covariate ranked highest is the most 
important one to adjust for and each subsequent covariate becomes less so.
28
 The 
top ranks can then be used in a model building procedure to determine the most 
appropriate multivariate model in terms of both the precision of the estimate of 
the treatment effect and the extent to which it maintains the type I error. 
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5.3 Application 
5.3a RAMPART  
 The Rapid Anti-Convulsant Medication Prior to Arrival Trial 
(RAMPART) was a randomized double dummy phase III clinical trial designed to 
test whether intramuscular (IM) midazolam was non-inferior by a margin of 10% 
to intravascular (IV) lorazepam for the treatment of status epilepticus, 
operationally defined as a seizure lasting at least five minutes without 
interruption.  Because the disease is life-threatening, the paramedics needed to 
administer the treatment immediately upon arrival. Thus, this study was 
conducted in an ambulatory setting under exception from informed consent, and 
the randomization scheme did not allow for any covariate adjustments.
40
  Subjects 
were well balanced between treatment groups on demographic and clinical 
characteristics, and the primary outcome of seizure termination prior to ED arrival 
without the use of rescue medication was met for 329 of 448 (73.4%) subjects 
allocated to active IM treatment and in 282 of 445 (63.4%) allocated to active IV 
treatment (risk difference (RD): 10.1%, 95% CI: 4.0%,16.1%). Thus, the trial 
results showed that IM midazolam was actually superior to IV lorazepam.
39
 The 
primary analysis did not adjust for any pre-specified prognostic variables. 
However, this secondary analysis explores whether or not the inclusion of some 
subset of available covariates may improve the precision and conservativeness of 
the treatment effect. 
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 The statistic for importance was calculated for several potential covariates 
of interest including subsequent ICU admission, hospital admission, intubation, 
recurrent seizure within 12 hours, hypotension, Hispanic ethnicity, type of 
seizure, prior history of seizure, low dose vs high dose, non-white race, pediatric 
vs adult, intubation within 30 minutes, recurrent seizure, and gender.  Table 5.3a.1 
gives the various components of the statistic for importance, including 𝑟1 (the 
correlation between treatment and covariate), 𝑟2 (a function of the correlations 
between covariate and outcome and treatment and outcome), 𝑍𝐷 (the statistic for 
disparity), and 𝑍𝐼
∗ (the statistic for influence), as well as the estimate of the 
treatment effect on the risk difference scale, including the associated 95% 
confidence interval and bias.   
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The table is currently sorted by Z Importance, which is a weighted product of 
𝑍𝐷 and 𝑍𝐼
∗  minus the adjusted Z value. Thus, it represents a joint measure of 
disparity and influence.  By ranking the covariates in this manner, we are able to 
not only identify the most important subset in terms of both the point estimate 
itself and its precision, but also to consider covariates relative to each other.  
Other rankings can be explored. For example, if one were concerned with 
precision, one might choose to rank by 𝑍𝐷. In this case, hospital admission would 
surpass ICU admission as the top ranked covariate.  However, if the goal was 
accuracy, one might chose to use 𝑍𝐼
∗ instead, revealing intubation, ICU admission, 
and intubation within 30 minutes.  Intubation within 30 minutes is now among our 
top three because it has a large 𝑟2 relative to the others.  However, if we are 
interested in both the point estimate and its precision, we would not want to 
choose intubation within 30 minutes as its 𝑟1 is quite small. Figure 5.3a.1 
illustrates the impact on the treatment estimate on the risk difference scale when a 
specific covariate is included in the model. 
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Figure 5.3a.1: Treatment Estimates and 95% Confidence Intervals for Covariates 
in RAMPART. Each Model Contains Treatment Plus One Covariate. 
 
Those covariates with high values of 𝑟1 and 𝑟2 in the same direction pull the point 
estimate of the treatment effect down (toward the null hypothesis) regardless of 
whether that direction is postive or negative, whereas those covariates with 
correlations in oppostie directions (i.e., one postive and one negative) pull the 
estimate up.  Thus, when controlling for type I error is the goal, as it should be 
given the increased potential under the non-inferioirty design, those covariates 
with correlation not in opposition are ranked highest. For the top ranked 
covariates, both the treatment estimate and the variance are reduced and this 
reduction is less pronounced as we move through the ranks.  Figure 5.3a.2 shows 
the values of Z importance for the covariates.  
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Figure 5.3a.2: Z Importance for Covariates in RAMPART 
 
The same information that is presented in Figure 5.3a.1 is quantified in Z 
Importance.  From the “elbow” in the curve, it is clear that two, or perhaps three, 
covariates are worth further evaluation.  These are ICU admission, hospital 
admission, and intubation.  For the analysis model, ICU admission and hospital 
admission cannot both be included in the analysis because of the high probability 
of co-linearity, so we can choose the higher ranked of these and conduct the 
analysis adjusting for ICU admission and intubation. Figure 5.3a.3 illustrates the 
unadjusted and adjusted confidence intervals for the treatment effect. 
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Figure 5.3a.3: Impact of Adjustment Using Z Importance in RAMPART  
 
Although we will never reach the non-inferiority bound set for this trial            
(RD = -10%) due to the inherent superiority of IM Midazolam that was confirmed 
in the trial, we can see that the adjusted analysis shifts the point estimate toward 
the null hypothesis in this setting, protecting against the probability of committing 
a type I error. Furthermore, we have discovered a more precise estimate of the 
treatment effect in this study. 
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5.3b RAMPART Pediatric Population 
 As the RAMPART study represents the largest prospective clinical trial 
experience with prehospital status epilepticus (SE) in children and adolescents, a 
secondary analysis was performed to describe and clinically characterize this 
unique cohort.  Of the 893 subjects in the primary intent to treat analysis, 120 
were less than 18 years of age.  As in the primary analysis, the pediatric 
population was well balanced across treatment groups in terms of demographic 
and clinical characteristics, and the primary outcome of seizure termination prior 
to ED arrival without the use of rescue medication was met for 41 of 60 (68.3%) 
patients randomized to active IM treatment and 43 of 60 (71.7%) randomized to 
active IV (RD: -3.3%, 99% CI=-24.9%, 18.2%).  Although the study was not 
powered for a secondary analysis of the pediatric population, IM Midazolam did 
not indicate superiority over IV Lorazepam as it did in the primary analysis. 
However, it did show non-inferiority in that the 99% confidence interval included 
the 10% non-inferiority margin.  Furthermore, there were some important 
differences favoring IM Midazolam in the pediatric population that were not 
evident in the cohort as a whole including lower rates of recurrent seizure, 
intubation, and ICU admittance.
43
 Thus, additional analyses that account for these 
covariates may reveal important findings in the cohort in addition to improving 
the accuracy and precision of the treatment estimate.  
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 The statistic for the importance of adjustment was calculated for the same 
covariates considered above with the exception of hypotension as none of subjects 
in the pediatric population met this criterion. Table 5.3b.1 provides the values of 
Z Importance, as well as its components, and the treatment estimates.  
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The covariates in Table 5.3b.1 are ranked by Z Importance, which represents a 
weighted product of the Z for disparity (𝑍𝐷) and the Z for influence (𝑍𝐼
∗) minus 
that adjusted Z value.  If one were to evaluate 𝑟1 (or 𝑍𝐷) in isolation, recurrent 
seizure (and the further refined recurrent seizure within 12 hours) would show the 
greatest imbalance across treatment arms.  However, imbalance alone is not 
sufficient to justify inclusion of covariates in analysis.  In fact, as described 
previously, covariates must be both disparate and influential to have important 
implications for the treatment effect, and the 𝑟2 (or 𝑍𝐼
∗) for these are quite low in 
comparison to the other available covariates.  Similarly, non-white race shows 
high influence, but low disparity.  Figure 5.3b.1 illustrates this impact for all 
available covariates in terms of point estimates and confidence intervals.  
Figure 5.3b.1 Treatment Estimates and 95% Confidence Intervals for Covariates 
in Pediatric Sub-Population of RAMPART. Each Model Contains Treatment Plus 
One Covariate. 
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In the pediatric cohort, as with the population as a whole, the covariates with 
correlation in the same direction pull the point estimate of the treatment effect 
down (towards the null hypothesis), while those with opposing correlations pull it 
up.  It is those covariates that pull it down which are important to include in order 
to maintain type I error.  However, the relative impact on the point estimate and 
its variance diminishes as we continue to add covariates to the model.  Figure 
5.3b.2 provides the distribution of the values of Z Importance, which can be used 
to determine the best number of covariates for inclusion.  
 
Figure 5.3b.2: Z Importance for Covariates in Pediatric Sub-Population of 
RAMPART 
 
The distribution in Figure 5.3b.2 does not show the same plateau effect as in the 
combined population of children and adults (Figure 5.3a.2), making the decision 
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less obvious.  Thus, one might chose to evaluate several models for sensitivity.  In 
this case, however, the issue of collinearity resurfaces.  The top ranked covariates, 
in order of importance, are intubation, Hispanic ethnicity, ICU admission, hospital 
admission, and intubation within 30 minutes of ED arrival.  The top three are 
likely to require inclusion, while hospital admission and intubation within 30 
minutes are more debatable.  As before, in the event of likely collinearity, it is 
reasonable to take the higher ranked covariate in each case.  Thus, the most 
conservative and precise estimate of treatment effect results from adjustment for 
intubation, Hispanic ethnicity, and ICU admission.  Figure 5.3b.3 provides this 
estimate and its 95% confidence interval along with the unadjusted estimate for 
comparison. 
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Figure 5.3b.3: Impact of Adjustment Using Z Importance in Pediatric Sub-
Population of RAMPART 
 
The inclusion of intubation, Hispanic ethnicity, and ICU admission provides a 
more precise estimate of the treatment effect, and, although the overall finding of 
the trial has not been changed, the use of the joint statistic for disparity and 
influence has revealed a more conservative model. 
 
5.4 Discussion 
 Failure to adjust for important covariates in non-inferiority trials can have 
serious implications for type I error (claiming a treatment is non-inferior when it 
Fail 
To 
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truly is inferior).
18.27
  As such, we need to make special efforts to protect against 
type I errors when operating under this framework.  A statistic for the importance 
of including a given covariate in analysis has been previously developed by the 
authors and combines information about a covariate’s imbalance across treatment 
groups and influence on outcome. This statistic can be calculated for all available 
covariates in a trial and used to rank them.  Based on the distribution of these 
values, an appropriate number of covariates can be selected for inclusion in 
analysis.  The end result will be an estimate of treatment effect that more precise.  
Furthermore, the inclusion of variables based on this method will ensure 
conservative estimates in terms of type I error under a non-inferiority study 
design.
28
  
 When applied to a real trial dataset, the statistic was able to identify those 
variables that maximized the tradeoff between changes in the point estimate itself 
and its precision and produced conservative estimates of treatment effect.  
Although the inclusion of the covariates in analysis did not change the overall 
conclusions of either trial, both resulted in a more conservative measure of the 
assumed treatment effect.  One limitation of this work is that some of the 
covariates under consideration, such as intubation, recurrent seizure, and hospital 
or ICU admission, may not necessarily constitute prognostic factors as they were 
often obtained after the assessment of primary outcome.  Future work needs 
evaluate the properties of the statistic for continuous or time to event outcomes 
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and formally compare the operating characteristics of this data driven approach to 
covariate selection to other available methods, particularly in terms of type I error. 
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Chapter 6  
Overall Conclusions 
 
 This proposed work offers insight into an important issue that has been 
overlooked by much the methodological literature in the non-inferiority setting, 
namely the impact of covariate adjustment.  Too often, trialists have taken the 
lessons learned from superiority and applied them directly to the non-inferiority 
framework.  However, this practice is inherently flawed due to the differential 
specification of the hypotheses
5
, and in fact, for many of the effects found in 
superiority, just the opposite is true in non-inferiority.  In this setting, failing to 
adjust for covariates results in treatment estimates that are biased towards zero 
with standard errors that are deflated.  This results in some increase in power, but 
also in a dramatic increase in type I error rates in the non-inferiority setting.
27
  
This presents a real danger for those trialists who may have unknown covariates 
or may prefer unadjusted analyses for parsimony or more straightforward 
interpretation. 
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 In RAMPART, the pre-hospital setting of the intervention made covariate 
adjusted randomization impossible. Therefore complete randomization and an 
unadjusted primary analysis were conducted.
40
 However, the current work 
suggests that the treatment effect estimate may be more precise and accurate 
given a prognostic covariate even if it were unknown to investigators.  Results 
from Aim 1 suggest that it would have been appropriate to adjust for covariates in 
the analysis even if adjustment at randomization was impossible as this results in 
unbiased treatment estimates and nominal type I error. Given that no known 
covariates were available at the start of the trial, an alternate method may have 
been that employed by Aim 2.  This data driven approach would have allowed us 
to investigate possible covariate effects in the data without knowing their 
prognostic value in advance and may have resulted in less extreme increases in 
type I error.  Just as it is recommended to conduct both intention to treat (ITT) 
and per protocol (PP) analyses in non-inferiority trials, trialists may also wish to 
present both unadjusted and adjusted analyses according to this method when 
covariates are not known in advance.  Thus, this proposed dissertation work (1) 
quantifies the impact of failing to adjust for covariates in terms of bias, power, 
and type I error, (2) develops a data driven joint statistic to quantify the impact of 
adjustment for a covariate given its influence and disparity, and (3) evaluates its 
potential via practical application. 
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